Assessing the uptake of the type 1 diabetes core outcome set in randomized controlled trials: A Cross-Sectional study
Authors' conclusion
Despite the 2017 T1D COS publication, use has decreased over time. This inconsistency negatively influences evidence-based practices and care. Educating researchers on COS and promoting uptake is crucial. Wider COS adoption in T1D trials could enhance clinical research overall. Further study of barriers and facilitators influencing uptake is essential to support consistent use and reporting.
Study context
- Population
- T1D RCTs registered on ClinicalTrials.gov (searched June 26, 2023); Core outcome set (COS) of eight key outcomes from the Core Outcome Measures in Effectiveness Trials (COMET) database
- Participants
- 144 RCTs
- Exposure
- COS uptake before vs after its release in December 2017
- Outcome
- Uptake of the T1D core outcome set (COS) and trends in its use before and after its development
Methodological detailsmasked, duplicate review by independent reviewers, 3,792 articles screened
- Masked, duplicate review by independent reviewers
- 3,792 articles screened
Main finding
As reported in the abstract
COS uptake
- Following COS publication, its use steadily decreased
Observational data: associations, not effects.
Further findings
Most frequently reported COS outcomes
- HbA1c and severe hypoglycemia most frequently implemented as endpoints; other recommended outcomes rarely used
Original publication
Assessing the uptake of the type 1 diabetes core outcome set in randomized controlled trials: A Cross-Sectional study. Diabetes Res Clin Pract. Published 7 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →